Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q4 2016 · 10-K
Revenue$255.66M$255.66M+6.0% vs Q4 2015 Net Income$28.25M$28.25M+88.6% vs Q4 2015 EPS Diluted$0.35$0.35+75.0% vs Q4 2015 Gross Profit$170,242,000+12.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$6,529,000−74.5% Free Cash Flowderived-$14,663,000N/M Margins · derivedGross margin66.6%+3.9 pt vs Q4 2015
Operating margin15.9%+6.0 pt vs Q4 2015
Net margin11.0%+4.8 pt vs Q4 2015
ended Dec 31, 2016 · filed Feb 23, 2017 · 54 d after period end